New strategies in anti-vascular cancer therapy

European Journal of Clinical Investigation

Volumn 29, Issue 9, 1999, Pages 802-809

  Bloemendal, H J ^a   Logtenberg, T ^a   Voest, E E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Phase display; Single chain antibodies; Vascular targeting

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; MELPHALAN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENDOTHELIUM, VASCULAR; MICROCIRCULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE LIBRARY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032833251     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00534.x     Document Type: Review

References (78)

1. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med, 1971;285 (21):1182-6.
2. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Eng J Med 1995;333 (26): 1757-63.
3. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med, 1995;1 (2):149-53.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996;86 (3):353-64.
5. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol, 1996;16 (9):4604-13.
6. Los M, Aarsman CJ, Terpstra L et al. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann Oncol, 1997;8 (10): 1015-22.
7. Shima DT, Adamis AP, Ferrara N et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med, 1995;1 (2):182-93.
8. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA, 1995;92 (3):768-72.
9. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-I. Science, 1994;265 (5178): 1582-4.
10. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res, 1995;55 (20):4575-80.
11. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 1990;348 (6301):555-7.
12. Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE. Clinical research on antiangiogenic therapy. Pharmacol Res, 1998;37 (1):1-16.
13. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 1993;362 (6423):841-4.
14. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994;79 (7):1157-64.
15. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest, 1995;96 (4):1815-22.
16. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis tung carcinoma [see comments]. Cell, 1994;79 (2):315-28.
17. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary, tumors in mice. Nat Med, 1996;2 (6):689-92.
18. O'Reilly MS, Bochm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997;88 (2):277-85.
19. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does net induce acquired drug resistance. Nature, 1997;390 (6658):404-7.
20. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther, 1994;65 (3):265-311.
21. Voest EE. Inhibitors of angiogenesis in a clinical perspective. Anticancer Drugs, 1996;7 (7):723-7.
22. Millauer B, Wizigmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72 (6):835-46.
23. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA, 1993;90 (16):7533-7.
24. De Vries C, Escobedo JA, Uenn H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 1992;255 (5047):989-91.
25. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 1991;6 (9):1677-83.
26. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev, 1996;7 (3):259-70.
27. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 1994;367 (6463):576-9.
28. Millauer B, Longhi MP, Plate KH et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res, 1996;56 (7):1615-20.
29. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87 (7):1161-9.
30. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 1997;277 (5322):55-60.
31. Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376 (6535):70-4.
32. Asahara T, Chen D, Takahashi T et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF- induced postnatal neovascularization. Circ Res, 1998;83 (3):233-40.
33. Kaipainen A, Vlaykova T, Hatva E et al. Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res, 1994;54 (24):6571-7.
34. Peters KG, Coogan A, Berry D et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer, 1998;77 (1):51-6.
35. Hatva E, Bohling T, Jaaskelainen J, Persico MG, Haltia M, Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol, 1996;148 (3):763-75.
36. Lin P, Buxton JA, Acheson A et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A, 1908;95 (15):8829-34.
37. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell, 1997;91 (4):439-42.
38. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol, 1996;7 (3):147-54.
39. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost, 1997;78 (1):285-96.
40. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994;264 (5158):569-71.
41. Brooks PC. Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev, 1996;15 (2):187-94.
42. Denekamp J, Hobson B. Endothelial-cell proliferation in experimental tumours. Br J Cancer, 1982;46 (5):711-20.
43. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev, 1990;9 (3):267-82.
44. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer, 1982;4S (1):136-9.
45. Kim DK, Kinne DW, Former JG. Occlusion of the hepatic artery in man. Surg Gynecol Obstet, 1973;136 (6):966-8.
46. Chuang VP, Wallace S. Current status of transcatheter management of neoplasms. Cardiovasc Intervent Radiol, 1980; 3 (4):256-67.
47. Kato T, Nemoto R, Mori H, Takahashi M, Tamakawa Y, Harada M. Arterial chemoembolization with microencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects. JAMA, 1981;245 (11):1123-7.
48. Chuang VP, Wallace S. Chemoembolization: transcatheter management of neoplasms. JAMA, 1981;245 (11):1151-2.
49. Kato T, Nemoto R, Mori H, Takahashi M, Harada M. Arterial chemoembolization with mitomycin C microcapsules in the treatment of primary or secondary carcinoma of the kidney, liver, bone and intrapelvic organs. Cancer, 1981;48 (3):674-80.
50. Chuang VP, Wallace S, Gianturco C, Soo CS. Complications of coil embolization: prevention and management. AJR Am J Roentgenol, 1981;137 (4):809-13.
51. Chuang VP, Wallace S, Swanson DA. Technique and complications of renal carcinoma infarction. Urol Radial, 1981;2 (3):223-8.
52. Strawitz JG, Wolferth CCJ, Howard JM, Grotzinger PJ. Treatment of advanced cancer by isolation perfusion. Arch Surg, 1965;91 (4):678-83.
53. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol, 1992;10 (1):52-60.
54. Hggermont AM, Schraffordt KH, Lienord D et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for non-resectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol, 1996;14 (10):2653-65.
55. Ruegg C, Yilmaz A, Bieler G, Barnat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med, 1998;4 (4):408-14.
56. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 1997;275 (5299):547-50.
57. Neri D, Carnemolla B, Nissim A et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol, 1997;15 (12):1271-5.
58. Ergun S, Kilic N, Fiedler W, Mukhopadhyay AK. Vascular endothelial growth factor and its receptors in normal human testicular tissue. Mol Cell Endocrinol, 1997;131 (1):9-20.
59. Simon M, Grone HJ, Johren O et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol, 1995; 268 (2):F240-F250.
60. Ergun S, Harneit S, Paust HJ, Mukhopadhyay AK, Holstein AF. Endothelin and endothelin receptors A and B in the human testis [In Process Citation]. Anal Embryol (Berl), 1998;199 (3):207-14.
61. Henry PJ. Endothelin receptor distribution and function in the airways [In Process Citation]. Clin Exp Pharmacol Physiol, 1999;26 (2):162-7.
62. Fujimura Y, Kihara T. Immunohistochemical localisation of intercellular adhesion molecule-1 in follicle associated epithelium of Peyer's patches. Gut, 1994;35 (1):46-50.
63. Perry ME, Kirkpatrick WN, Happerfield LC, Gleeson MJ. Expression of adhesion molecules on the microvasculature of the pharyngeal tonsil (adenoid). Acta Otolaryngol)(Stockh), 1996;523 (suppl):47-51.
64. Burton DR, Barbas CF. Human antibodies from combinatorial libraries. Adv Immunol, 1994;57:191-280.
65. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol, 1994;12:433-55.
66. Van Ewijk W, de Kruif J, Germeraad WT et al. Subtractive isolation of phage-displayed single-chain antibodies to thymic stromal cells by using intact thymic fragments. Proc Natl Acad Sci USA, 1997;94 (8):3903-8.
67. de Kruif J, Terstappen L, Boel E, Logtenberg T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc Natl Acad Sci USA, 1995;92 (9):3938-42.
68. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature, 1996;380 (6572):364-6.
69. Pasqualini R, Koivunen F, Ruoslahti E. Alpha v integrins as receptor for tumor targeting by circulating ligands. Nat Biotechnol, 1997;15 (6):542-6.
70. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998;279 (5349): 377-80.
71. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest, 1998;102 (2):430-7.
72. Schier R, McCall A, Adams GP et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol, 1996;263 (4):551-67.
73. Schier R, Marks JD. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas, 1996;7 (3):97-105.
74. de Kruif J, Storm G, van Bloois L, Logtenberg T. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett, 1996;399 (3):232-6.
75. de Kruif J, Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J Biol Chem, 1996;271 (13): 7630-4.
76. Carnemolla B, Neri D, Castellani P et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer, 1996;68 (3):397-405.
77. Palmer DB, George AJ, Ritter MA. Selection of antibodies to cell surface determinants on mouse thymic epithelial cells using a phage display library. Immunology, 1997;91 (3): 473-8.
78. Bloemendal HJ, Logtenberg T, de Boer HC, Koop EA, Voest EE, Gebbink MFBG. Targeting tumour vasculature with single chain antibodyfragments against the activated form of vitronectin. Proceedings of the American Association of Cancer Research, Abstract number 2766, 1999.